Description
Contents: Package Insert, Quick Reference Instructions, 25 each of – Test Devices, Buffer solution, Nasal swabs
Regulatory Status: FDA EUA authorized, CLIA Waived
Determinations: Detection of COVID-19 (SARS-CoV-2)
Processing Time: 10 Minutes
The COVID-19 rapid antigen point-of-care test gives health care professionals a reliable, efficient testing solution for use in CLIA-waived settings. Designed for ease of use and quick result interpretation, it supports timely decision-making at the point of care.
Features:
- Simple: Minimal training required
- Efficient: No equipment necessary
- Flexible: From clinics to congregate living environments
- Bulk-Testing: Our rapid COVID-19 test allows for the aggregate collection of multiple specimens followed by batch-testing of individual samples up to two (2) hours after collection
- Detects COVID-19 subvariants: To date, in-house analytical studies have not identified any variants of concern that have an impact to the performance of INDICAID, including Omicron sub-variants BA.4, BA.5, BQ.1, BQ.1.1, XBB.1.5, and XBB.1.16.
Product Resources:
